Syndel’s Syncaine vet.® (Trikainmesilat) Granted Norwegian Medical Products Agency (NOMA) Authorization for Use in Norway
Bringing Innovative Aquaculture Health Solutions to a Key Market
FOR IMMEDIATE RELEASE
Ferndale, WA – September 2025 – Syndel, a recognized global leader in aquaculture health solutions, announces that its flagship product, Syncaine vet.® (Trikainmesilat), has received formal approval from the Norwegian Medical Products Agency (NOMA) for application within Norway. This important development highlights Syndel’s continued commitment to delivering dependable and innovative fish health solutions to the worldwide aquaculture sector.
About Syncaine vet.® (Trikainmesilat)
Produced in North America, Syncaine vet.® is authorized in multiple countries for the temporary immobilization of Atlantic salmon, rainbow trout and cod. With Norway positioned as a leading market for aquaculture, the NOMA approval enables the introduction of Syncaine vet.® to this strategically significant region.
Company Statement
“Receiving NOMA approval for Syncaine vet.® in Norway represents a key advancement for Syndel,” stated Jason Montgomery, Global Sales Manager at Syndel. “We are dedicated to extending our global portfolio and supporting aquaculture professionals as they pursue operational excellence and optimal animal welfare.”
Distribution in Norway
Syncaine vet.® will be distributed in Norway via VESO. Since 1988, VESO has been a leading player in fish health and veterinary medicine. VESO has a strong foundation in research and innovation, offering solutions and products that promote animal health, infection control and sustainable production.
Contact Information
Syndel USA
Phone: 1-800-283-5292
Email: [email protected]
Website: www.syndel.com
VESO AS
Phone: +47 22 96 11 00
Email: [email protected]
Order-related inquiries: [email protected]
Website: www.veso.no/en/locations/norway
